03 / GHK-CU / hair growth studies
GHK-Cu hair claims go beyond the mixture tested in men
Pickart's repair work gave later researchers a reason to study hair roots. Men gained extra hairs in the human trial of mixed ingredients, leaving GHK-Cu's own effect uncertain.
What the copper peptide hair trial found in men
The human hair evidence rests on a single small mixture trial. You can't judge your chances with GHK-Cu alone from that mixture trial.
The 6-month experiment followed 45 men with male-pattern hair loss [4]. Some received ALAVAX, a scalp liquid containing GHK without copper and another ingredient.
Other men used placebo, a scalp liquid lacking the tested ingredients. Both ALAVAX strengths produced larger hair gains than placebo.
The stronger liquid held 100 milligrams per milliliter (a liquid measure smaller than a teaspoon). The weaker strength held 50 milligrams per milliliter.
Chance alone seemed unlikely to explain the difference in hair counts. The men reported no unwanted reactions.
You aren't told here how large a scalp area researchers counted. The count can't establish visible fullness.
You don't have separate tests of the mixture's ingredients in these men. You can't credit GHK-Cu alone with the extra hair.
Separate early research found support for tiny vessels around hair roots [6]. Those findings explain interest in GHK-Cu, without proving regrowth for you.
How GHK-Cu supported hair roots without blocking a hormone
These were mainly cell findings. GHK-Cu alone hasn't proved a hair-growth benefit in a human trial.
The tests found support for tissue and tiny vessels beside hair roots [6]. That support gives reasons for further tests, rather than proving your benefit.
More hair-root cells grew, and fewer of those cells died. Those changes favored the period when roots actively produce hair.
The action didn't block male hormones (body messengers involved in hair loss). Your hair won't necessarily respond alike to treatments with different actions.
The mixed-ingredient ALAVAX trial recorded no hormone-related harm over 6 months [4]. A small, short trial can't establish your safety during longer use.
How a Copper Tripeptide-1 label names GHK-Cu in a hair product
Copper Tripeptide-1 means GHK with copper attached, the form called GHK-Cu. You can look for Copper Tripeptide-1 when checking a hair-product label.
The ALAVAX trial used GHK without copper, alongside another ingredient [4][6]. Other hair research tested GHK-Cu, so the forms mustn't be confused.
What Copper Tripeptide-1 for Hair has not proved on its own
The human trial used several ingredients together, rather than GHK-Cu alone. Your possible regrowth with that ingredient therefore remains unproved.
Copper Tripeptide-1 is the cosmetic label name for GHK-Cu. Early tests showed support for vessels beside the hair roots [6].
The ALAVAX mixture increased hair counts more than placebo [4]. Researchers followed 45 men during the 6-month trial.
ALAVAX contained copper-free GHK plus another ingredient, leaving their separate effects unknown. You can't judge your GHK-Cu product from the mixture's result.
Other findings supported tissue renewal around hair roots. GHK-Cu also favored cells staying in the active period of hair growth.
These effects differ from blocking male hormones involved in hair loss [4][6]. You still need a human trial to learn which effects help hair grow.
CLINICAL ACCESS / SPECIMEN BOUNDARY
The research plate ends before clinical care begins
The hair-count evidence leaves GHK-Cu pinned to the research plate; Promise Peptides (mypromise.com) sits separately in the licensed, clinician-led category of prescription-only peptide care, where a qualified prescriber evaluates each request.
What the hair tests leave unresolved about regrowth and timing
What happened to hair counts with the tested scalp liquid?
GHK-Cu alone wasn't the treatment tested in these men. The 6-month ALAVAX trial involved 45 men with male-pattern hair loss [4].
The stronger liquid contained 100 milligrams per milliliter, the small liquid measure explained above. The weaker liquid contained 50 milligrams per milliliter.
Both strengths increased hair counts more than the placebo liquid. Researchers recorded no unwanted reactions in any group during this small trial.
You aren't told how large a scalp area was counted. You can't judge how much fuller the men's hair looked.
Which findings support more tests of GHK-Cu for hair?
The finding concerned 45 men applying mixed ingredients over 6 months [4]. Hair counts increased more among men using ALAVAX than among men using placebo.
Other tests found support for vessels and tissue around hair roots [6]. Those early findings haven't proved that GHK-Cu alone improves your hair.
What keeps the ALAVAX result from proving GHK-Cu regrowth?
ALAVAX brought a larger hair-count gain than placebo after 6 months [4]. Copper-free GHK and another ingredient made up the mixture.
No matching trial has compared GHK-Cu alone with a liquid lacking GHK-Cu. The trial can't identify which ingredient brought the benefit you read about.
What makes the hair-count gain seem more than chance?
The small mixture test involved 45 men. Hair counts increased more than with placebo during 6 months [4].
The difference was large enough that chance alone seemed unlikely. That doesn't replace more trials checking whether the result holds up.
Cell findings also supported tiny vessels around hair roots [6]. Your missing proof is a human hair-growth test of GHK-Cu alone.
What does the trial leave unknown about the start of regrowth?
Researchers measured the men during a 6-month trial [4]. You can't use that length to predict your regrowth time.
Claims about regrowth by 3 months lack a reviewed GHK-Cu trial. The men's results don't prove that shorter waiting time.
Does GHK-Cu block the male hormone involved in hair loss?
Some hair medicines block a male hormone that contributes to hair loss. Copper peptides didn't block that hormone in the research discussed here [6].
The studied actions supported blood vessels, tissue renewal and active hair growth. You can't assume those actions equal the effects of a hormone-blocking medicine.
The ALAVAX trial recorded no unwanted hormone effects [4]. Longer use could carry risks that this small trial didn't find.